Allergan didn't buy Heptares.
"Under the terms of the agreement, Heptares will receive an upfront payment of $125 million and is eligible to receive contingent milestone payments of up to approximately $665 million associated with the successful Phase 1, 2 and 3 clinical development and launch of the first three licensed compounds for multiple indications and up to approximately $2.5 billion associated with achieving certain annual sales thresholds during the several years following launch. In addition, Heptares is eligible to receive up to double-digit tiered royalties on net sales of all products resulting from the partnership. Allergan is also committing up to $50 million to a research and development program to be conducted jointly by Allergan and Heptares aimed at advancing multiple candidates through Phase 2 clinical studies. Allergan will be responsible for the development of licensed compounds upon initiation of Phase 2b studies and for subsequent manufacturing and commercialization of the products.
The agreement covers first-in-class selective small molecule agonists targeting muscarinic M1 and M4 receptors in the brain, discovered using Heptares’ proprietary StaR® technology platform. Allergan will receive exclusive rights to a broad clinical and preclinical portfolio of M1, M4 and dual M1/M4 agonists, including HTL9936 and HTL18318, selective M1 agonists currently in Phase 1 clinical development."
They stated all patients/caregivers requested continuing treatment.
Should be noted that 2 patients discontinued treatment (not drug related), so there are 30 patients going forward (Part B) not 32.
Why would Pfizer or any pharma partner now?
Why not wait and see if results hold up in a larger blinded study?
I'd rather they focus on getting the phase 2b or 3 up and running before starting another indication.
Either way, they're going to need some money.
No mention from company about adding patients, so I'll assume they were not replaced with new patients.
Also, since they discontinued treatment, their data would be excluded.
Only 30 patients going forward. Two discontinued treatment unrelated to study drug (page 7 of November presentation).